Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy

A K Simonds, F Muntoni, S Heather, S Fielding

Abstract

Background—Respiratory failure is the commonest cause of death in patients with Duchenne muscular dystrophy (DMD). Life expectancy is less than one year once diurnal hypercapnia develops. This study examines the effects of nasal intermittent positive pressure ventilation (NIPPV) on survival in symptomatic Duchenne patients with established ventilatory failure.

Methods—Nocturnal NIPPV was applied in 23 consecutive patients with DMD of mean (SD) age 20.3 (3.4) years who presented with diurnal and nocturnal hypercapnia.

Results—One year and five year survival rates were 85% (95% CI 69 to 100) and 73% (95% CI 53 to 94), respectively. Early changes in arterial blood gas tensions following NIPPV occurred with mean (SD) PO$_2$ increasing from 7.6 (2.1) kPa to 10.8 (1.3) kPa and mean (SD) PCO$_2$, falling from 10.1 (4.5) kPa to 6.1 (1.0) kPa. Improvements in arterial blood gas tensions were maintained over five years. Health perception and social aspects of SF-36 health related quality of life index were reported as equivalent to other groups with non-progressive disorders using NIPPV.

Conclusion—Nasal ventilation is likely to increase survival in hypercapnic patients with Duchenne muscular dystrophy and should be considered as a treatment option when ventilatory failure develops. (Thorax 1998;53:949–952)

Keywords: Duchenne muscular dystrophy; nasal intermittent positive pressure ventilation; mortality

In patients with Duchenne muscular dystrophy (DMD) a characteristic pattern of respiratory function is seen during childhood and adolescence. Vital capacity (VC) increases as predicted until around 10 years of age. A plateau then occurs followed by a steady fall in VC as respiratory muscle weakness progresses, accompanied by the development of a thoracic scoliosis in the majority of cases. The annual decrease in VC may be as much as 250 ml in the late teenage years.¹ Once VC falls below 20% predicted ventilatory failure is almost inevitable, with 73% of DMD patients dying of respiratory insufficiency.² About 10% die of a cardiomyopathy which may be exacerbated by chronic hypoxaemia and hypercapnia. Hypoventilation, sometimes associated with obstructive apnoeas,³ first occurs during sleep as a result of the reduction in intercostal and accessory muscle tone, and a decrease in ventilatory drive which is most prominent in rapid eye movement (REM) sleep. Untreated, nocturnal hypoventilation progresses to daytime ventilatory failure and ultimately cor pulmonale. Acute hypercapnic exacerbations complicate the clinical course and are usually caused by chest infections as inspiratory muscle weakness predisposes the individual to atelectasis, and cough is impaired by expiratory muscle insufficiency.

A study in which normocapnic DMD patients with a vital capacity of 20–50% predicted were randomised to receive nasal ventilation or a control group without ventilatory support showed that nasal ventilation had no beneficial effect on survival and was poorly tolerated.⁴ By contrast, mean survival after diurnal hypercapnia develops in DMD is 9.7 months without ventilatory assistance.⁵ In patients with established ventilatory failure nasal ventilation can be life saving.⁶ It has been argued that it is unethical to deny ventilatory assistance to hypercapnic DMD patients as death is the inevitable consequence of withholding treatment.⁷ Information on the survival and quality of life in patients with DMD with hypercapnic respiratory failure receiving assisted ventilation is sparse. There are reports of negative pressure ventilation in DMD,⁸ ⁹ although this is not the treatment of choice as upper airway obstruction during sleep may be provoked.¹⁰ Mouth ventilation has been successful in some centres¹¹ but long term survival using non-invasive techniques is not well documented. In the largest study of NIPPV in DMD 16 patients were treated initially with nasal ventilation, but five were transferred to tracheostomy ventilation (T-IPPV).¹² Despite the fact that nasal ventilation was pioneered in patients with DMD,¹³ a progressive care plan of non-invasive ventilation followed by T-IPPV, or T-IPPV alone, is the norm in many European countries. This complicates management as tracheostomy ventilation is more difficult to deliver in the home than non-invasive ventilation and may delay or prevent discharge. In addition, most patients and their carers prefer non-invasive methods where these can be used safely.¹⁴ In this study hypercapnic DMD patients have been treated solely with long term domiciliary nasal ventilation to examine the impact of NIPPV on survival, arterial blood gas tensions, and health related quality of life.

Methods

Twenty three consecutive patients referred to the Royal Brompton Hospital are included in the analysis. A diagnosis of DMD was made...
according to standard criteria.16 All patients were non-ambulant by the age of 12 years and none had features of Becker muscular dystrophy. Five were referred from intensive care units elsewhere with uncontrolled acute on chronic hypercapnic respiratory failure. After weaning using nasal ventilation, domiciliary ventilation was initiated if diurnal hypercapnia and severe symptomatic nocturnal hypoventilation (PCO2 >7 kPa) persisted in a steady state period on recovery. Eighteen patients were treated electively for symptomatic daytime hypercapnia and confirmed nocturnal hypoventilation. Vital capacity was unrecordable at the start of nasal ventilation in 10 patients.

The patients all used domiciliary nasal ventilators at night in assist/control mode. No preference was given to any particular type of nasal ventilator as a previous study in this unit using pressure preset and volume preset devices produced similar effects on arterial blood gas control and respiratory muscle effort.17 Twenty subjects used pressure preset devices, 16 Nippy (Friday Medical, London, UK), two BiPAP (Respironics Inc, Murrysville, USA), two DP90 (Taema, Deva Medical, Runcorn, UK) and three used volume preset models (PLV-100, Lifecare, Lafayette Co, USA or BromptonPAC, Pneupac Ltd, Luton, UK). Commercial nasal interfaces, the Rescare bubble mask, (Resmed Ltd, Abingdon, UK), Respironics nasal mask, (Respironics, Murrysville, USA) or Adams circuit, (Puritan Bennett, Hounslow, UK) were employed according to patient preference. Ventilation was started in hospital in all cases and overnight monitoring of arterial oxygen saturation (SaO2) and transcutaneous CO2 was carried out to optimise control of nocturnal hypoventilation with the aim of maintaining SaO2 at >90% and transcutaneous CO2 in the normal range.18 Inspiratory pressures of 16–28 cm H2O were used and expiratory positive pressures of 2–5 cm H2O where the latter was available.

Patients were advised to use domiciliary nasal ventilation during sleep at night. Supplemental oxygen therapy was not used. Carers and family members were taught to perform daily chest physiotherapy for the patients during nasal ventilation to improve sputum clearance. A modified active cycle of breathing technique was used to achieve effective coughing. Inspiratory pressure or tidal volume were temporarily increased by around 20% during physiotherapy sessions to increase inspiratory volume, and manual chest clapping and shaking were combined with assisted coughing/huffing.19 Humidification via a heated water bath system (Resmed) was added in some patients at the time of acute chest infections, but was not used long term. Outpatient review was carried out every 3–6 months.

Ventilators were serviced in the patient’s home at 6–12 month intervals and all patients/carers had access to a hospital 24 hour telephone respiratory support hotline service to report equipment problems or seek medical advice. Thirteen of 18 surviving patients completed the SF-36 questionnaires on health related quality of life 3–72 months after starting nasal ventilation.

## Results

Patient characteristics before the start of nasal ventilation are given in table 1. All patients tolerated nasal ventilation and none requested to discontinue therapy. Kaplan-Meier analysis showed one year survival was 85% (95% CI 69 to 100) with 73% survival (95% CI 53 to 94) at two years which was maintained at five years (fig 1). Arterial PO2 and PCO2, by the time of discharge improved significantly on NIPPV (fig 2) and these improvements were sustained over

### Table 1: Patient characteristics on starting nasal ventilation (n = 23)

<table>
<thead>
<tr>
<th></th>
<th>Values Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) [median]</td>
<td>20.3 (3.4) [20.0] 13–28</td>
</tr>
<tr>
<td>PaO2 (kPa)</td>
<td>7.57 (2.1) 4.0-12.8*</td>
</tr>
<tr>
<td>Paco2 (kPa)</td>
<td>10.26 (4.5) 6.4-24</td>
</tr>
<tr>
<td>Vital capacity (ml)</td>
<td>306 (146) 0-600</td>
</tr>
</tbody>
</table>

Values are mean (SD). * Measured on supplemental oxygen therapy.
Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy

Figure 3 Evolution of arterial blood gas tensions during treatment with NIPPV in patients treated electively (diurnal values obtained with patients breathing air spontaneously).

Figure 4 Health related quality of life SF-36 results. DMD = Duchenne muscular dystrophy; Polio = post polio patients; COPD = chronic obstructive pulmonary disease (all on NIPPV); HP = health perception; PF = physical function; SF= social function; RLP = role limitation related to physical factors; RLM = role limitation related to mental factors; MH = mental health; EV = energy and vitality; 0 = minimum score; 100 = maximum score except for pain where 0 = maximum pain and 100 = no pain.

Discussion

Domiciliary nasal ventilation is established treatment for patients with ventilatory failure due to restrictive chest wall disease and non-progressive neuromuscular conditions such as previous poliomyelitis affecting respiratory muscles. Previous it was thought that non-invasive ventilation could not be used as the sole means of ventilatory support in patients with DMD as loss of bulbar function and poor expiratory muscle strength would necessitate tracheostomy ventilation later in the course of the disease. Ethical concerns have been expressed that the use of NIPPV in a progressive disease such as DMD would be a burden to the patient and family, and likely to result in poor survival and a severely impaired quality of life. The findings presented here contradict these widely held views.

Although an uncontrolled series, the results confirm that long term survival can be achieved with NIPPV. This impact of NIPPV on prolongation of life can only be speculative as we felt it unethical to include an unventilated group of hypercapnic DMD patients. However, previous studies have consistently shown a life expectancy of around 20 years in untreated patients, suggesting that NIPPV may extend survival in some patients by five years or more. Direct comparison with the outcome in patients with DMD who have received T-IPPV is difficult as many are treated with a range of ventilatory methods before a tracheostomy is carried out.

Quality of life in NIPPV recipients is comparable to other patient groups with non-progressive disorders, despite a lower level of physical function. The effect of NIPPV on the quality of life of the patient’s family/carers remains to be assessed. Hospitalisation rates were generally low and no patient required admission to the intensive care unit.

NIPPV offers the advantage of allowing normal speech and feeding, and avoids complications related to a tracheal stoma such as tracheal stenosis and nosocomial infection. Volume preset ventilators have been used by previous workers but this study would suggest that pressure preset ventilators are at least as effective. Some patients may benefit from a combination of mouth ventilation and NIPPV. Meticulous attention to physiotherapy during NIPPV is essential in patients with profoundly weak expiratory muscles, and is crucial to the success of the technique. Bach et al have shown that the combination of non-invasive ventilation and cough aids produces lower hospitalisation rates than T-IPPV, although survival rates are not given. T-IPPV may still be needed in some individuals, but progression
from non-invasive to invasive ventilation should not be seen as inevitable. This is important as T-IPPV is technically more demanding to deliver in the home than nasal ventilation, and it is much more difficult for individuals to attend higher education courses or to travel if they are dependent on T-IPPV. It should also be acknowledged that in some countries there is a reluctance to use tracheostomy ventilation in progressive neuromuscular disease, although in this study T-IPPV remained an option if problems developed with nasal ventilation.

Negative pressure ventilation (nPV) is a non-invasive alternative to NIPPV. Using body suit nPV a maximum survival of four years was seen in one series of nine patients with DMD, but the increase in diurnal Pao2 did not match that obtained in the present study. Overnight monitoring during nPV has confirmed recurrent episodes of arterial oxygen desaturation due to obstructive apnoeas which were abolished by the addition of nasal continuous positive airway pressure, but not by supplemental oxygen therapy. By promoting upper airway patency during sleep, NIPPV is likely to control sleep disordered breathing more effectively than nPV resulting in improved diurnal arterial blood gas tensions. This mechanism could explain the survival advantage seen with NIPPV.

The results suggest that the option of nasal ventilation should be available to all patients with DMD who choose to receive ventilatory support. The study can be criticised in that measurements of health status and respiratory muscle strength before and after NIPPV would have been preferable; however, many patients were too ill to complete these assessments on admission. It will only be possible to obtain serial assessment before and after NIPPV if patients are referred for respiratory management before the development of ventilatory failure.

An interesting feature is the plateau in survival over years one to four. More work is required to examine whether the improvement in arterial blood gas tensions leads to a stabilisation in respiratory muscle strength and/or cardiac function over this period. Finally, a significant number of patients presented in uncontrolled ventilatory failure, having been lost to medical follow up since discharge from paediatric care. Most patients had experienced symptoms of nocturnal hypoventilation (headaches, poor sleep quality, anorexia, breathlessness) and an increased frequency of chest infections for a few years before developing ventilatory failure. Many teenage patients had not transferred adequately from paediatric to adult medical care services, or adult respiratory follow up had been discontinued. Improved liaison between paediatricians and adult physicians is likely to reduce the number of patients with DMD (and those with other congenital muscular dystrophies and myopathies) who develop uncontrolled ventilatory failure, and to allow patients and their families to consider ventilatory options in advance. This process may be facilitated by the establishment of adolescent neuromuscular clinics where neurological, respiratory, cardiac and orthopaedic care, plus nutritional and physiotherapy advice can be co-ordinated. From References 1 to 22.
Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy

A K Simonds, F Muntoni, S Heather and S Fielding

Thorax 1998 53: 949-952
doi: 10.1136/thx.53.11.949

Updated information and services can be found at:
http://thorax.bmj.com/content/53/11/949

These include:

References
This article cites 17 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/53/11/949#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Muscle disease (36)
- Neuromuscular disease (86)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/